Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
Rakesh Sahay, Dinesh Gangwani, Manish Singh, Sandeep Gupta, Narendra Kale, Manoj Srivastava, Prakash Kurmi, Jayesh Ambaliya, Nilesh Lomte, Sandip Gofne, Saurabh Agarwal, Priyanka Kashid, Vikas Agarwal, Pradeep Rai, Surendra Sharma, L Sreenivasa Murthy, Mandodari Rajurkar, Shruti Saha, Piyush Patel, Dipak Patil, Pravin Ghadge, Lalit Lakhwani, Suyog Mehta, Sadhna J Joglekar
Diabetes Obes Metab 27(4) 2193-2205
摘要
摘要
AIM: To evaluate the efficacy and safety of a triple fixed-dose combination (FDC) therapy of dapagliflozin + glimepiride + metformin hydrochloride extended-release (DAPA + GLIM + MET ER) tablets in Indian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by combination of GLIM + MET. MATERIALS AND METHODS: A phase III, randomized, open-label, active-controlled study was conducted for a maximum 30 weeks (primary treatment [16 weeks]; uptitration [12 weeks] and follow-up [2 weeks]). Eligible patients were randomized in a 1:1 ratio to receive either the FDC of DAPA + GLIM + MET ER or the FDC of GLIM + MET prolonged-release (PR) once-daily. The primary efficacy endpoint was a change in glycated haemoglobin (HbA1c) from baseline to week 16. RESULTS: The mean reduction in HbA1c from baseline to week 16 was significantly greater with the FDC of DAPA + GLIM + MET ER compared to the FDC of GLIM + MET PR (-1.98% ± 1.01% vs. -1.64% ± 0.86%, p = 0.0047). The mean reduction in HbA1c from baseline to week 12 was significantly greater with the FDC of DAPA + GLIM + MET ER versus dual FDC (p < 0.0001). The proportion of patients achieving HbA1c <7.0% was significantly greater with the FDC of DAPA + GLIM + MET ER versus dual FDC at week 12 (19.1% vs. 6.5%; p = 0.0002) and week 16 (52.6% vs. 36.7%; p = 0.0015). A significant decrease in HbA1c, fasting and post-prandial blood glucose from baseline to weeks 12, 16, and 28 was observed in both arms. The incidence of TEAEs was similar across both arms. CONCLUSION: This study demonstrated that the FDC of DAPA + GLIM + MET ER tablets once daily was significantly better than dual FDC in achieving glycaemic control in patients with poorly controlled T2DM. Both treatments were well-tolerated. TRIAL REGISTRATION: CTRI/2022/03/041424, registered on 28 March 2022.
KM 提取结果
0 个 Figure · 0 个 KM 面板